+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID05691491

Phase 12 Study of Temozolomide and M1774 for Treating Advanced or Metastatic Solid Tumors

Led by National Cancer Institute (NCI) · Updated on 2026-07-31

42

Participants Needed

23

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a combination of two anti-cancer drugs, temozolomide and M1774 also called tuvusertib, in patients with advanced metastatic cancer that has spread from its original site to other parts of the body. This phase III trial aims to find the best tolerated dose of this combination and study its side effects, as well as to observe its anti-tumor activity and effects on progression-free and overall survival. The study also explores biological markers related to treatment response and tumor characteristics. Participants receive oral doses of tuvusertib daily on days 1 through 7 and temozolomide daily on days 1 through 5 of each 28-day cycle. Treatment cycles continue until disease progression or unacceptable side effects occur. Throughout the trial, patients undergo CT scans, MRI scans, blood sample collections, and tumor biopsies at the start and possibly during or at progression of the study. During the study, researchers monitor dosing limits, tumor response rates, survival outcomes, and safety events. After completing treatment, participants have a follow-up visit at 4 weeks if needed, then regular check-ups every 3 months for up to 2 years. This schedule helps evaluate long-term effects and treatment outcomes while ensuring close observation of patient health.

CONDITIONS

Brief Title

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here